These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6527945)

  • 21. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of the staging system proposed by Merlini, Waldenström and Jayakar for multiple myeloma.
    Bettini R; Steidl L; Rapazzini P; Giardina G
    Acta Haematol; 1983; 70(6):379-85. PubMed ID: 6417962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of MRI for the diagnosis and prognosis of multiple myeloma.
    Baur-Melnyk A; Buhmann S; Dürr HR; Reiser M
    Eur J Radiol; 2005 Jul; 55(1):56-63. PubMed ID: 15950101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of criteria in staging in multiple myeloma.
    Pennec Y; Mottier D; Youinou P; Asselain B; Miossec P; Le Goff P; Le Prise PY; Le Menn G
    Haematologia (Budap); 1982; 15(2):221-6. PubMed ID: 7160667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.
    Shimamoto Y
    Cancer Detect Prev; 1995; 19(5):426-35. PubMed ID: 7585729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and staging in multiple myeloma: a reappraisal.
    Bataille R; Durie BG; Grenier J; Sany J
    J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Merlini, Waldenström, Jayakar staging system revisited.
    Merlini G; Gobbi PG; Ascari E
    Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A comparison of staging classifications of plasmacytoma].
    Löffler H; Gassmann W; Haferlach T; Pralle H
    Onkologie; 1986 Aug; 9(4):196, 199-201. PubMed ID: 3531946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multiple myeloma. Role of prognostic factors and staging in a therapeutic program].
    Bolis S; Bregani ER; Rossini F; Casaroli I; Lanzi E; Maffè P; Baldicchi L; Borin L; Mingozzi S; Tripputi P
    Recenti Prog Med; 1994 Jan; 85(1):49-55. PubMed ID: 8184181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
    Kyrtsonis MC; Maltezas D; Tzenou T; Koulieris E; Bradwell AR
    Semin Hematol; 2009 Apr; 46(2):110-7. PubMed ID: 19389494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of nucleo-cytoplasmic maturation asynchrony in multiple myeloma.
    Scudla V; Wiedermann B; Kodousek R; Dusek J; Kamarád V; Indrák K
    Neoplasma; 1986; 33(4):483-92. PubMed ID: 3762809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
    Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Staging systems for multiple myeloma: a comparison.
    Gassmann W; Pralle H; Haferlach T; Pandurevic S; Graubner M; Schmitz N; Löffler H
    Br J Haematol; 1985 Apr; 59(4):703-11. PubMed ID: 3986136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current and future approaches to therapy for multiple myeloma].
    Nara N
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):9-15. PubMed ID: 7826084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Contesting a critique of the comparison of 2 prognostic classifications of multiple myeloma].
    Pesce A; Cassuto JP; Grisot C; Gratecos N; Bayle J; Viot G; Dujardin P
    Nouv Rev Fr Hematol (1978); 1984; 26(6):401. PubMed ID: 6527946
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prognostic factors of multiple myeloma].
    Paule B
    Ann Med Interne (Paris); 1997; 148(8):534-41. PubMed ID: 9538400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple myeloma: prognostic factors and treatment modalities.
    Michiels JJ
    Neth J Med; 1992 Jun; 40(5-6):254-70. PubMed ID: 1436263
    [No Abstract]   [Full Text] [Related]  

  • 40. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.